Galera Therapeutics Inc
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treat… Read more
Galera Therapeutics Inc (GRTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.016x
Based on the latest financial reports, Galera Therapeutics Inc (GRTX) has a cash flow conversion efficiency ratio of 0.016x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.34 Million) by net assets ($-143.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Galera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Galera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Galera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galera Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Westar Resources Ltd
AU:WSR
|
-0.269x |
|
Badlands Resources Inc
PINK:BDLNF
|
0.021x |
|
Australasian Metals Ltd
AU:A8G
|
-0.053x |
|
LDB Capital Corp.
V:LDB-P
|
0.062x |
|
NOVARTIS N (NOT.SG)
STU:NOT
|
0.145x |
|
OSHKOSH (OK3.SG)
STU:OK3
|
0.079x |
|
Jaya Swarasa Agung PT
JK:TAYS
|
0.001x |
|
Nickelsearch Ltd
AU:NIS
|
-0.589x |
Annual Cash Flow Conversion Efficiency for Galera Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Galera Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-143.67 Million | $-12.14 Million | 0.085x | -75.27% |
| 2023-12-31 | $-131.19 Million | $-44.85 Million | 0.342x | -14.05% |
| 2022-12-31 | $-109.18 Million | $-43.43 Million | 0.398x | -66.05% |
| 2021-12-31 | $-58.00 Million | $-67.96 Million | 1.172x | +112.04% |
| 2020-12-31 | $6.12 Million | $-59.54 Million | -9.731x | -1351.72% |
| 2019-12-31 | $69.61 Million | $-46.66 Million | -0.670x | -416.99% |
| 2018-12-31 | $-104.82 Million | $-22.17 Million | 0.211x | -31.24% |
| 2017-12-31 | $-76.11 Million | $-23.41 Million | 0.308x | -- |